Spero Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on May 29, 2024, specifically the Company's Annual Meeting of Stockholders. Spero Therapeutics, Inc. is a Delaware corporation headquartered in Cambridge, Massachusetts, with common stock trading on The Nasdaq Global Select Market under the symbol SPRO.
Key Financial Metrics
This filing is a current report regarding corporate governance and stockholder actions. It does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to the Company's most recent Form 10-K or 10-Q for financial statements.
Material Changes and Corporate Actions
The filing details the following material actions approved by stockholders at the Annual Meeting:
- Stock Incentive Plan Amendment: Stockholders approved an amendment to the 2017 Stock Incentive Plan to increase the number of authorized shares for issuance by 3,000,000 shares.
- Board of Directors Election: Three Class I directors were reelected to serve until the 2027 annual meeting:
- Scott Jackson
- John C. Pottage, Jr., M.D.
- Cynthia Smith
- Independent Auditor Ratification: PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Executive Compensation: The advisory vote on the compensation of named executive officers was approved.
Voting Results and Participation
As of the record date (April 5, 2024), there were 53,892,889 shares eligible to vote. A quorum of 36,772,282 shares (68.23%) was present. Key voting outcomes included:
- Director Elections: All nominees received significant support, with "Votes For" ranging from approximately 23.0 million to 24.5 million. Broker non-votes totaled 12,035,616 for director elections.
- Auditor Ratification: 36,628,785 votes For vs. 137,585 votes Against.
- Compensation Advisory Vote: 23,890,281 votes For vs. 442,014 votes Against.
- Stock Plan Amendment: 22,794,466 votes For vs. 1,882,600 votes Against.
Outlook, Risks, and Contingencies
This filing does not contain management commentary on future outlook, specific risks, or contingencies beyond the standard incorporation by reference of the 2017 Plan text and the Proxy Statement filed on April 16, 2024.
Key Facts for Investor Verification
- Verify the impact of the 3,000,000 share increase to the 2017 Stock Incentive Plan on potential future dilution.
- Review the full text of the 2017 Stock Incentive Plan (Exhibit 10.1) for specific terms regarding vesting and exercise.
- Confirm the tenure of the reelected directors (Scott Jackson, John C. Pottage, Jr., and Cynthia Smith) extending through the 2027 annual meeting.
- Note that this filing contains no financial data; refer to recent 10-Q/10-K filings for liquidity and operational status.